European Investment Bank president, Nadia Calviño, during her official appointment in Warsaw, visited headquarters of Scope Fluidics, a first in the CEE region medtech Venture Studio, beneficiary of EIB venture debt instrument, which proved to be a crucial funding source on a way to perform the largest transaction in the history of Polish life science sector.
Nadia Calviño, European Investment Bank President said:
Scope Fluidics is a great example of a European deeptech success story. Our cooperation was a crucial partnership during Covid times. The EIB support for innovative companies in Poland is helping to reinforce Europe’s economy and its competitiveness.
Prof. Piotr Garstecki, Scope Fluidics co-founder and Chief Executive Officer said:
It’s a great honour for us to host President Nadia Calviño here at Scope Fluidics. We appreciate this another example of support that EIB is providing to us in the recent years. As a former EIB venture debt instrument beneficiary, just a week ago we participated in the EIB European Venture Debt Summit, held in Luxembourg, where we had a chance to take part in discussions dedicated to the development of European innovations ecosystem. We are more than happy because of our fruitful cooperation and looking forward our another joint success stories in the future.
During her visit at Scope Fluidics, Nadia Calviño met with company team members and took part in a facility tour including presentation of the BACTEROMIC system, a groundbreaking technology in a fight against rising worldwide antimicrobial resistance pandemic and a current flagship project under development by Scope Fluidics.
In September 2020, during the coronavirus pandemic, Scope Fluidics received up to €10 million in debt financing under a joint initiative of the European Commission and the European Investment Bank Group – the InnovFin Infectious Diseases Finance Facility (IDFF), designed to help innovative players in the development of vaccines, drugs, medical and diagnostic devices and research infrastructure in the fight against infectious diseases. In 2020, the facility became a vehicle for the European Union to support the global fight against the COVID-19 pandemic.
The funds from the EIB were used to develop PCR|ONE technology, among other things. In August 2022, Scope Fluidics sold 100% of Curiosity Diagnostics, which was developing PCR|ONE, a breakthrough system for rapid PCR analysis in a point-of-care format, to US industry giant Bio-Rad Laboratories. The upfront payment was valued at $100 million.
